Heartseed

Near-clinical-stage biotech company developing iPSC-derived highly purified ventricular cardiomyocytes for heart failure.

Launch date

Jan 2015

Employees

Market cap

Enterprise valuation

AUD286m (Public information from May 2023)

Tokyo Japan (HQ)

http://heartseed.jp

https://www.linkedin.com/company/heartseed-inc

Date	Investors	Amount	Round
-	Angel Bridge Astellas Venture Shibuya Corporation JMDC Japan	N/A	-
Jan 2015	The University of Tokyo	N/A	Spinout
Mar 2016*	Bridge Angel Investors	JPY100m	Seed
Jul 2017	N/A	JPY250m	Series A
Nov 2017	N/A	JPY250m	Series A
Jul 2018	Astellas Pharma	$7.2m	Series A
Nov 2019	Nissay Capital SMBC Venture Capital SBI Investment Gene Techno Science	$26.0m	Series B
Mar 2020	N/A	$960k	Early VC
Aug 2020	N/A	JPY77.0m	Series B
Jun 2021	Nissay Capital SMBC Venture Capital SBI Investment UTokyo Innovation Platform Sumitomo Mitsui Trust Investment Keio Innovation Initiative Medical Incubator Japan Medipal Holdings Itochu Chemical Frontier	$37.0m	Series C
May 2023*	SMBC Venture Capital UTokyo Innovation Platform Sumitomo Mitsui Trust Investment Keio Innovation Initiative Japan Co-Invest Limited Partnership Medical Incubator Japan Nikon-SBI Innovation Fund Arcus Investment Koei Tecmo Capital Atsushi Sakano	$14.4m Valuation: $185m	Series D
Total Funding		AUD140m